Meningococcal Group B Vaccine (Bexsero) is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B (see Pharmacology: Pharmacodynamics: Pharmacodynamic effects under Actions for information on protection against specific group B strains).
The use of Meningococcal Group B Vaccine (Bexsero) should be in accordance with official recommendations.
Other Services
Country
Account